Micafungin versus liposomal amphotericin b for pediatric patients with invasive candidiasis: Substudy of a randomized Double-blind trial

Pediatric Infectious Disease Journal

Volumn 27, Issue 9, 2008, Pages 820-826

  Queiroz Telles, Flavio ^a   Berezin, Eitan ^b   Leverger, Guy ^c   Freire, Antonio ^b   Van Der Vyver, Annalie ^d   Chotpitayasunondh, Tawee ^e   Konja, Josip ^f   Diekmann Berndt, Heike ^g   Koblinger, Sonja ^g   Groll, Andreas H ^h   Arrieta, Antonio ⁱ  

^a Nutrition and Diet Unit   (Brazil)

^b Santa Casa de Misericordia de Goiania   (Brazil)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d UNIVERSITY OF THE FREE STATE   (South Africa)

^e QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^f KBC Zagreb   (Croatia)

^g Astellas Pharma GmbH   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ Children's Hospital   (United States)

Author keywords

Double blind trial; Invasive candidiasis; Micafungin; Pediatric

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MICAFUNGIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPROTEIN;

ADOLESCENT; ANEMIA; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; GROUPS BY AGE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RISK FACTOR; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; CANDIDIASIS; COMPARATIVE STUDY; INFANT; NEWBORN; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ECHINOCANDINS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LIPOPROTEINS; TREATMENT OUTCOME;

EID: 53049099239     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31817275e6     Document Type: Article

References (30)

1. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and infiuences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
2. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect. 2005;11:908-913.
3. Pema ́n J, Canto ́n E, Gobernado M. Epidemiology and antifungal sus- ceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis. 2005;24: 23-30.
4. Boo TW, O'Reilly B, O'Leary J, Cryan B. Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses. 2005;48:251-259.
5. Kullberg BJ, Oude Lashof AML. Epidemiology of opportunistic inva- sive mycoses. Eur J Med Res. 2002;7:183-191.
6. Richardson MD. Changing patterns and trends in systemic fungal infec- tions. J Antimicrob Chemother. 2005;56:i5-i11.
7. Krcmery V, Laho L, Huttova M, et al. Aetiology, antifungal suscepti- bility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol. 2002;51:110-116.
8. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer. 2005;41:1439-1445.
9. Lo ́pez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicentre study of 118 cases. Am J P erinatol. 2003;20:153-163.
10. Fratarelli DAC, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs. 2004;64:949-968.
11. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23:1093-1097.
12. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective random- ized trial. Pediatr Infect Dis J. 1996;15:1107-1112.
13. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
14. Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Padiatr. 2005;217(Suppl 1):S37-S66.
15. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am. 2005;52:895-915.
16. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth weight infants: therapeutic toxicity. Pediatrics. 1984; 73:153-157.
17. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142- 1151.
18. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215-222.
19. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic ediat- ric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
20. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pedi- atr Infect Dis J. 2006;25:1110-1115.
21. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candi- demia. Eur J Clin Microbiol Infect Dis. 2005;24:654-661.
22. Kuse ER, Chetchotisakd P, Arns da Cunha C, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive can- didosis in a phase III, randomised double-blind trial. Lancet. 2007; 369:1519-1527.
23. Wingard JR, White MH, Anaissie E, Rafalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155-1163.
24. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am. 1987;34:571-590.
25. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized double- blind parallel-group dose-response study of micafungin compared with fiuconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842-849.
26. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. In: Final program of the 47th Interscience Conference on Antimicrobial Agents and Chemother- apy; September 17-20, 2007; Chicago, IL. Abstract A-776a.
27. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Can- dida meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
28. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from paediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol. 2002;40:852-856.
29. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibil- ity survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149-3154.
30. Pappas P, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-893.